文献速递妇科

老年妇科肿瘤患者化疗:表型衰弱评分能否预测耐受性?

Chemotherapy in older adult gynecologic oncology patients: Can a phenotypic frailty score predict tolerance?
PubMed 文献 · Gynecol Oncol · 2018-11-28

前瞻性单机构队列研究纳入80例65岁及以上开始化疗的妇科肿瘤患者,办公室表型衰弱评估包括Fried评分和FRAIL量表成分。衰弱与所有患者未启动标准疗化疗(SOCC)及辅助化疗患者无法完成SOCC相关,但与并发症和方案调整无关;年龄与SOCC、耐受或完成无关。

要点

  • 衰弱与所有患者未启动SOCC及辅助化疗患者无法完成SOCC相关。
  • 年龄与是否接受SOCC、化疗耐受或完成无关。
  • 表型衰弱评估预测效用有限,作者认为或有助于辅助化疗患者选择更温和方案。

核心结论

  • 需要开发工具帮助医生预测老年妇科肿瘤患者的化疗耐受性,以避免治疗不足和治疗过度并减少并发症。
  • 在本研究中,表型衰弱评估的预测效用有限。
  • 在辅助化疗患者中,衰弱与无法完成SOCC相关,因此可能有助于选择适合接受不那么积极化疗方案的患者。

研究设计与样本

  • 前瞻性单机构队列研究,纳入80例65岁及以上开始化疗的妇科肿瘤患者。
  • 在办公室访视时进行表型衰弱测试,包含Fried评分(身体测试和患者回答)和FRAIL量表(仅患者回答)两个已验证衰弱评估的成分。
  • 患者随访至新辅助化疗三个周期或辅助化疗六个周期。

主要发现

  • 80例患者中65%为卵巢癌,34%为子宫内膜癌。
  • 平均57%的患者为健康,32%为中间衰弱,11%为衰弱。
  • 68%接受辅助化疗,32%接受新辅助化疗;81%接受21天周期的静脉化疗,81%初始接受与标准疗化疗(SOCC)一致的方案。
  • 年龄与接受SOCC、化疗耐受或完成无关;衰弱与所有患者未启动SOCC及辅助化疗患者无法完成SOCC相关。
  • 并发症和方案调整常见,但与衰弱无关。

临床怎么用

  • 作者认为表型衰弱评估可能有助于选择适合接受不那么积极化疗方案的辅助化疗患者。
  • 原文未据此给出其他推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Evaluate the ability of an office-administered phenotypic frailty assessment to predict chemotherapy tolerance in older adult gynecologic oncology patients, and describe practice patterns for chemotherapy administration in this population. METHODS: Prospective, single-institution cohort study of gynecologic oncology patients 65 or older initiating chemotherapy. Phenotypic frailty testing at an office visit encompassed components of two validated frailty assessments: Fried Score (physical testing and patient response) and FRAIL Scale (patient response only). Patients were followed through three cycles of neoadjuvant chemotherapy or six cycles of adjuvant chemotherapy. Standard statistics examined the relationship of frailty to chemotherapy regimen, ability to complete chemotherapy, and complications. RESULTS: Eighty patients were included, 65% with ovarian and 34% with endometrial cancer. On average 57% of patients were fit, 32% intermediately frail, and 11% frail. 68% received adjuvant chemotherapy versus 32% neoadjuvant. The majority (81%) received IV chemotherapy on a 21-day cycle and 81% initially received a regimen consistent with standard-of-care chemotherapy (SOCC). Age was not associated with receiving SOCC, or tolerance or completion of chemotherapy. Frailty was associated with non-initiation of SOCC in all patients and inability to complete SOCC in adjuvant patients. Complications and regimen alterations were common but were not associated with frailty. CONCLUSIONS: There is a need to develop tools to help physicians predict chemotherapy tolerance among older adult gynecologic oncology patients in order to prevent both under- and over-treatment while minimizing morbidity. However, in this study phenotypic frailty assessment had limited predictive utility. Among adjuvant chemotherapy patients, frailty was associated with inability to complete SOCC and thus may be helpful in selecting patients appropriate for less aggressive chemotherapy regimens.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Hay CM, Donovan HS, Campbell GB, et al. Chemotherapy in older adult gynecologic oncology patients: Can a phenotypic frailty score predict tolerance? Gynecol Oncol. 2018. PMID: 30503049. doi:10.1016/j.ygyno.2018.11.031

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。